Login / Signup

Rozanolixizumab: A New Therapy in the Treatment of Myasthenia Gravis.

Emily M Hitt
Published in: The Annals of pharmacotherapy (2024)
The approval of rozanolixizumab represents an advancement in therapy for generalized myasthenia gravis. The provision of individualized, targeted, and well-tolerated treatment is valuable for the patients whose myasthenia gravis is not well controlled and who are seeking a medication with a rapid onset of action to improve their symptoms and overall quality of life.
Keyphrases